Clinical trial
A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma
NCT00352742 · Attenuon, Industry · Terminated
Key facts
| NCT number | NCT00352742 |
|---|---|
| Title | A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma |
| Official title | A Phase I/II Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma Relapsed From or Refractory to Bortezomib |
| Lead sponsor | Attenuon, Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | ATN-224 + bortezomib |
| Enrollment | 46 |
| Start date | Jun 1, 2006 |
| Primary completion | Sep 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Jul 17, 2006 |
| Last update posted | Oct 28, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: